Laboratory of Neurophysiology, Department of Physiology, University of Concepción, Concepción, Chile; Laboratory of Neurobiometals, Department of Physiology, University of Concepción, Concepción, Chile.
Neurobiol Aging. 2013 Dec;34(12):2805-14. doi: 10.1016/j.neurobiolaging.2013.06.001. Epub 2013 Jul 12.
A major characteristic of Alzheimer's disease is the presence of amyloid beta (Aβ) oligomers and aggregates in the brain. Aβ oligomers interact with the neuronal membrane inducing perforations, causing an influx of calcium ions and increasing the release of synaptic vesicles that leads to a delayed synaptic failure by vesicle depletion. Here, we identified a neuroprotective pentapeptide anti-Aβ compound having the sequence of the glycine zipper region of the C-terminal of Aβ (G33LMVG37). Docking and Förster resonance energy transfer experiments showed that G33LMVG37 interacts with Aβ at the C-terminal region, which is important for Aβ association and insertion into the lipid membrane. Furthermore, this pentapeptide interfered with Aβ aggregation, association, and perforation of the plasma membrane. The synaptotoxicity induced by Aβ after acute and chronic applications were abolished by G33LMVG37. These results provide a novel rationale for drug development against Alzheimer's disease.
阿尔茨海默病的一个主要特征是大脑中存在淀粉样β(Aβ)寡聚体和聚集体。Aβ 寡聚体与神经元膜相互作用诱导穿孔,导致钙离子内流和突触小泡释放增加,从而导致囊泡耗竭导致突触延迟衰竭。在这里,我们鉴定了一种具有 Aβ(G33LMVG37)C 端甘氨酸拉链区域序列的神经保护五肽抗 Aβ 化合物。对接和Förster 共振能量转移实验表明,G33LMVG37 在 C 端区域与 Aβ 相互作用,这对于 Aβ 结合和插入脂质膜很重要。此外,这种五肽干扰了 Aβ 的聚集、结合和质膜穿孔。急性和慢性应用 Aβ 诱导的突触毒性被 G33LMVG37 消除。这些结果为开发针对阿尔茨海默病的药物提供了新的依据。